D. Middlemiss

发表

8-Hydroxy-2-(di-n-propylamino)-tetralin discriminates between subtypes of the 5-HT1 recognition site.

D. Middlemiss, J. Fozard, 1983, European journal of pharmacology.

Quantitative mRNA analysis of five C-terminal splice variants of the human 5-HT4 receptor in the central nervous system by TaqMan real time RT-PCR.

D. Middlemiss, A. Medhurst, F. Lezoualc’h, 2001, Brain research. Molecular brain research.

The expression of GABAB1 and GABAB2 receptor subunits in the cNS differs from that in peripheral tissues

M. Pangalos, D. Middlemiss, G. Hervieu, 2000, Neuroscience.

A novel, potent, and selective 5-HT(7) antagonist: (R)-3-(2-(2-(4-methylpiperidin-1-yl)ethyl)pyrrolidine-1-sulfonyl) phen ol (SB-269970).

P J Lovell, J. Hagan, D. Middlemiss, 2000, Journal of medicinal chemistry.

Metitepine distinguishes two receptors mediating inhibition of [3H]-5-hydroxytryptamine release in guinea pig hippocampus

D. Middlemiss, L. Wilkinson, 1992, Naunyn-Schmiedeberg's Archives of Pharmacology.

SB 242084, a Selective and Brain Penetrant 5-HT2C Receptor Antagonist

A. Brown, D. Middlemiss, S. Bromidge, 1997, Neuropharmacology.

L‐694,247: a potent 5‐HT1D receptor agonist

D. Middlemiss, V. Matassa, R. Hargreaves, 1993, British journal of pharmacology.

An investigation of the 5-HT1D receptor binding affinity of 5-hydroxytryptamine, 5-carboxyamidotryptamine and sumatriptan in the central nervous system of seven species.

D. Middlemiss, M. Beer, J. Stanton, 1992, European journal of pharmacology.

Behavioural and biochemical evidence of the interaction of the putative antipsychotic agent, BMY 14802 with the 5-HT1A receptor.

D. Middlemiss, M. Tricklebank, L. Bristow, 1991, European journal of pharmacology.

[3 H]-SB-269970 radiolabels 5-HT7 receptors in rodent, pig and primate brain tissues

D. Middlemiss, P. Hastie, G. W. Price, 2002, Neuropharmacology.

SB‐272183, a selective 5‐HT1A, 5‐HT1B and 5‐HT1D receptor antagonist in native tissue

C. Davies, D. Middlemiss, C. Scott, 2001, British journal of pharmacology.

Pharmacological characterisation of human 5-HT2 receptor subtypes.

D. Middlemiss, M. Wood, D. Smart, 2001, European journal of pharmacology.

[3H]‐SB‐269970 – A selective antagonist radioligand for 5‐HT7 receptors

J. Hagan, D. Middlemiss, G. W. Price, 2000 .

Functional comparison of muscarinic partial agonists at muscarinic receptor subtypes hM1, hM2, hM3, hM4 and hM5 using microphysiometry

D. Middlemiss, M. Wood, J. Watson, 1999, British journal of pharmacology.

Characterization of the binding of [3H]‐SB‐204269, a radiolabelled form of the new anticonvulsant SB‐204269, to a novel binding site in rat brain membranes

D. Middlemiss, H. Herdon, N. Upton, 1997, British journal of pharmacology.

radiolabelled form of the new anticonvulsant SB-204269, to a novel binding site in rat brain membranes

D. Middlemiss, H. Herdon, N. Upton, 1997 .

The novel anticonvulsant SB 204269 binds to a stereospecific site in the mouse brain.

D. Middlemiss, H. Herdon, N. Upton, 1996, European journal of pharmacology.

Cardiovascular Response to 8-Hydroxy-2-(di-n-Propylamino) Tetralin (8-OH-DPAT) in the Rat: Site of Action and Pharmacological Analysis

D. Middlemiss, J. Fozard, A. Mir, 1987, Journal of cardiovascular pharmacology.

(R)-3,N-dimethyl-N-[1-methyl-3-(4-methyl-piperidin-1-yl) propyl]benzenesulfonamide: the first selective 5-HT7 receptor antagonist.

P J Lovell, J. Hagan, A. Brown, 1998, Journal of medicinal chemistry.

The selective 5-HT1B receptor inverse agonist 1'-methyl-5-[[2'-methyl-4'-(5-methyl-1,2, 4-oxadiazol-3-yl)biphenyl-4-yl]carbonyl]-2,3,6,7-tetrahydro- spiro[furo[2,3-f]indole-3,4'-piperidine] (SB-224289) potently blocks terminal 5-HT autoreceptor function both in vitro and in vivo.

J. Hagan, D. Middlemiss, G. W. Price, 1998, Journal of medicinal chemistry.

A functional correlate for the dihydropyridine binding site in rat brain

D. Middlemiss, M. Spedding, 1985, Nature.

Stimulation of 5-HT1B receptors causes hypothermia in the guinea pig.

J. Hagan, D. Middlemiss, P. Jeffrey, 1997, European journal of pharmacology.

[3H]ditolylguanidine binding to human brain σ sites is diminished after haloperidol treatment

G. Reynolds, D. Middlemiss, Jane E. Brown, 1991 .

The human σ site, which resembles that in NCB20 cells, may correspond to a low-affinity site in guinea pig brain

E. Wong, D. Middlemiss, A. R. Knight, 1991, Neuroscience Letters.

The calcium channel activator, bay K 8644, enhances K+-evoked efflux of acetylcholine and noradrenaline from rat brain slices

D. Middlemiss, 1985, Naunyn-Schmiedeberg's Archives of Pharmacology.

Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent.

D. Middlemiss, S. Lightowler, S. Bromidge, 2000, Journal of medicinal chemistry.

Measurement of the in vitro release of endogenous monoamine neurotransmitters as a means of identification of prejunctional receptors

D. Middlemiss, P. Hutson, 1990, Journal of Neuroscience Methods.

Characterization of recombinant human orexin receptor pharmacology in a Chinese hamster ovary cell‐line using FLIPR

D. Middlemiss, P. Murdock, N. Elshourbagy, 1999, British journal of pharmacology.

The anandamide transport inhibitor AM404 is an agonist at the rat vanilloid receptor (VR1)

D. Middlemiss, John B Davis, D. Smart, 2000 .

5-HT1D receptors

D. Middlemiss, V. Matassa, M. Beer, 1997 .

In Vitro Functional Correlates Of 5-HT,-Like Receptors

D. Middlemiss, L. Wilkinson, M. Beer, 1993 .

SB-236057-A: a selective 5-HT1B receptor inverse agonist.

D. Middlemiss, G. W. Price, J. Watson, 2006, CNS drug reviews.

SB-236057, a selective 5-HT1B receptor inverse agonist, blocks the 5-HT human terminal autoreceptor.

D. Middlemiss, C. Scott, G. W. Price, 1999, European journal of pharmacology.

The [3H]5-HT and [3H]spiroperidol binding sites in the rat frontal cortex and thermally inactivated at different rates.

D. Middlemiss, J. Carroll, D. Poller, 1981, European journal of pharmacology.

Does [3H]spiroperidol label a 5-HT receptor in the frontal cortex of the rat?

D. Middlemiss, J. Carroll, R. Fisher, 1980, European journal of pharmacology.

Studies on the role of 5-HT2C and 5-HT2B receptors in regulating generalised seizure threshold in rodents.

D. Middlemiss, T. Blackburn, G. Kennett, 1998, European journal of pharmacology.

Serotonin-5-O-carboxymethyl-glycyl[125I]tyrosinamide labels the 5-HT1D beta receptor subtype in human cortex.

D. Middlemiss, M. Beer, 1993, European journal of pharmacology.

Influence of peptide CRF receptor antagonists upon the behavioural effects of human/rat CRF.

J. Hagan, D. Middlemiss, R. Kortekaas, 1999, European journal of pharmacology.

Destruction of a sub-population of cortical neurones by suicide transport of volkensin, a lectin from Adenia volkensii

D. Middlemiss, P. Francis, R. Pearson, 1991, Journal of Neuroscience Methods.

Spiropiperidines as high-affinity, selective sigma ligands.

E. Wong, D. Middlemiss, D. Billington, 1992, Journal of medicinal chemistry.

The interaction of tyramine with a single dose of tranylcypromine in healthy volunteers.

D. Middlemiss, R. Yates, M. Peet, 1981, British journal of clinical pharmacology.

MK-212 increases rat plasma ACTH concentration by activation of the 5-HT1C receptor subtype

D. Middlemiss, C. Dourish, C. Brazell, 1989, Neuroscience Letters.

Cloning and characterization of human NTT5 and v7-3: two orphan transporters of the Na+/Cl- -dependent neurotransmitter transporter gene family.

M. Pangalos, D. Middlemiss, G. W. Price, 2000, Genomics.

The dosage of Co-trimoxazole in childhood

D. Middlemiss, A. Bye, A. Fowle, 1975, European Journal of Clinical Pharmacology.

Graphics computer-aided receptor mapping as a predictive tool for drug design: development of potent, selective, and stereospecific ligands for the 5-HT1A receptor.

D. Middlemiss, J. Fozard, M. Hibert, 1988, Journal of medicinal chemistry.

Direct evidence for an interaction of β-adrenergic blockers with the 5-HT receptor

D. Middlemiss, Louise Blakeborough, STEPHEN R. Leather, 1977, Nature.

Synthesis and serotonergic activity of 5-(oxadiazolyl)tryptamines: potent agonists for 5-HT1D receptors.

D. Middlemiss, V. Matassa, M. Beer, 1993, Journal of medicinal chemistry.

Synthesis and 5-hydroxytryptamine antagonist activity of 2-[[2-(dimethylamino)ethyl]thio]-3-phenylquinoline and its analogues.

D. Middlemiss, B. Cox, T. Blackburn, 1987, Journal of medicinal chemistry.

(–)Baclofen decreases neurotransmitter release in the mammalian CNS by an action at a novel GABA receptor

D. Middlemiss, N. Bowery, A. Hudson, 1980, Nature.

Cannabinoid activation of recombinant and endogenous vanilloid receptors.

D. Middlemiss, D. Kendall, D. Smart, 2001, European journal of pharmacology.

5-HT1-like receptors: six down and still counting.

D. Middlemiss, G. Mcallister, M. Beer, 1993, Trends in pharmacological sciences.

Dopamine D3 Receptor Antagonism Inhibits Cocaine-Seeking and Cocaine-Enhanced Brain Reward in Rats

J. Hagan, D. Middlemiss, G. Stemp, 2002, The Journal of Neuroscience.

SB-243213; a selective 5-HT2C receptor inverse agonist with improved anxiolytic profile: lack of tolerance and withdrawal anxiety

D. Middlemiss, S. Lightowler, S. Bromidge, 2001, Neuropharmacology.

Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine

P. Bradley, D. Middlemiss, J. Fozard, 1986, Neuropharmacology.

Autoreceptors Regulating Serotonin Release

D. Middlemiss, 1988 .

Stereoselective blockade at [3H]5-HT binding sites and at the 5-HT autoreceptor by propranolol.

D. Middlemiss, 1984, European journal of pharmacology.

K+-evoked [3H]-5-HT release from rat frontal cortex slices: the effect of 5-HT agonists and antagonists.

D. Middlemiss, J. Carroll, R. Fisher, 1982, Biochemical pharmacology.

PHARMACOKINETIC INTERACTION BETWEEN PROPRANOLOL AND CHLORPROMAZINE IN SCHIZOPHRENIC PATIENTS

D. Middlemiss, R. Yates, M. Peet, 1980, The Lancet.

Propranolol in Schizophrenia

D. Middlemiss, R. Yates, M. Peet, 1981, British Journal of Psychiatry.

5-Chloro-N-(4-methoxy-3-piperazin-1-yl- phenyl)-3-methyl-2-benzothiophenesulfon- amide (SB-271046): a potent, selective, and orally bioavailable 5-HT6 receptor antagonist.

A. Brown, D. Middlemiss, S. Bromidge, 1999, Journal of medicinal chemistry.

Parkinson's disease: prospects for improved drug therapy.

J. Hagan, D. Middlemiss, G. Poste, 1997, Trends in pharmacological sciences.

Molecular cloning and characterization of two novel retinoic acid-inducible orphan G-protein-coupled receptors (GPRC5B and GPRC5C).

M. Pangalos, D. Middlemiss, A. Medhurst, 2000, Genomics.

In vitro characterisation of the muscarinic receptor partial agonist, sabcomeline, in rat cortical and heart membranes.

A. Brown, D. Middlemiss, J. Watson, 1999, European journal of pharmacology.

The behavioural effects of corticotropin-releasing factor-related peptides in rats

J. Hagan, D. Middlemiss, R. Kortekaas, 1998, Psychopharmacology.

5-Hydroxytryptamine receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database

G. Martin, J. Hensler, R. Hen, 2019, IUPHAR/BPS Guide to Pharmacology CITE.

Monoamine receptor sensitivity changes following chronic administration of MDL 72394, a site-directed inhibitor of monoamine oxidase.

D. Middlemiss, J. Fozard, M. Tricklebank, 1986, European journal of pharmacology.

Chapter 5. Drugs Acting at Central 5-Hydroxytryptamine Receptors

D. Middlemiss, J. Fozard, M. Hibert, 1986 .

Characterization of SB‐269970‐A, a selective 5‐HT7 receptor antagonist

J. Hagan, D. Middlemiss, G. W. Price, 2000, British journal of pharmacology.

Characterization of [(125)I]-SB-258585 binding to human recombinant and native 5-HT(6) receptors in rat, pig and human brain tissue.

D. Middlemiss, G. W. Price, S. Bromidge, 2000, British journal of pharmacology.

Molecular cloning of a serotonin receptor from human brain (5HT1E): a fifth 5HT1-like subtype.

L L Iversen, L. Iversen, D. Middlemiss, 1992, Proceedings of the National Academy of Sciences of the United States of America.

Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A.

J. Hagan, D. Middlemiss, K. Thewlis, 2000, The Journal of pharmacology and experimental therapeutics.

Spironolactone causes a rapid down regulation of sigma recognition sites in guinea pig brain and liver

D. Middlemiss, A. R. Knight, C. Wyatt, 1991, Neuropharmacology.

Blockade of the central 5-HT autoreceptor by β-adrenoceptor antagonists☆

D. Middlemiss, 1986 .

SB‐656104‐A, a novel selective 5‐HT7 receptor antagonist, modulates REM sleep in rats

J. Hagan, D. Middlemiss, C. Scott, 2003, British journal of pharmacology.

Comparison of the functional potencies of ropinirole and other dopamine receptor agonists at human D2(long), D3 and D4.4 receptors expressed in Chinese hamster ovary cells

J. Hagan, D. Middlemiss, T. Brown, 1999, British journal of pharmacology.

MDL 72832: a potent and stereoselective ligand at central and peripheral 5-HT1A receptors.

D. Middlemiss, J. Fozard, E. Kidd, 1988, European journal of pharmacology.

The 5‐HT1B Receptors

D. Middlemiss, D N Middlemiss, P. Hutson, 1990, Annals of the New York Academy of Sciences.

Species differences in the pharmacology of terminal 5-HT autoreceptors in mammalian brain.

D. Middlemiss, D. Hoyer, 1989, Trends in pharmacological sciences.

Low pH modulation of recombinant vanilloid receptors and perivascular capsaicin-sensitive sensory neurotransmission

D. Middlemiss, D. Kendall, John B Davis, 2001, Autonomic Neuroscience.

Receptor-mediated control of neurotransmitter release from brain slices or synaptosomes.

D. Middlemiss, 1988, Trends in pharmacological sciences.

Failure of ω-conotoxin to block L-channels associated with [3H]5-HT release in rat brain slices

D. Middlemiss, D. Hill, I. Rijnhout, 1990, Neuroscience Letters.

SB‐224289–a novel selective (human) 5‐HT1B receptor antagonist with negative intrinsic activity

D. Middlemiss, C. Scott, G. W. Price, 1998, British journal of pharmacology.

Effects of selective h5-HT1B (SB-216641) and h5-HT1D (BRL-15572) receptor ligands on guinea-pig and human 5-HT auto- and heteroreceptors

D. Middlemiss, J. Zentner, G. W. Price, 1997, Naunyn-Schmiedeberg's Archives of Pharmacology.

SB-216641 and BRL-15572 – compounds to pharmacologically discriminate h5-HT1B and h5-HT1D receptors

M. J. Burton, L. Gaster, D. Middlemiss, 1997, Naunyn-Schmiedeberg's Archives of Pharmacology.

Functional effects of the muscarinic receptor agonist, xanomeline, at 5‐HT1 and 5‐HT2 receptors

D. Middlemiss, G. Riley, J. Watson, 1998, British journal of pharmacology.

Serotonergic targets in depression.

D. Middlemiss, G. W. Price, J. Watson, 2002, Current opinion in pharmacology.

Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone.

C. Langmead, J. Hagan, D. Middlemiss, 2005, European journal of pharmacology.

The putative 5‐HT1 receptor agonist, RU 24969, inhibits the efflux of 5‐hydroxytryptamine from rat frontal cortex slices by stimulation of the 5‐HT autoreceptor

D. Middlemiss, 1985, The Journal of pharmacy and pharmacology.

5‐CT stimulation of adenylyl cyclase activity in guinea‐pig hippocampus: evidence for involvement of 5‐HT7 and 5‐HT1A receptors

D. Middlemiss, S. G. Taylor, David R. Thomas, 1999, British journal of pharmacology.

Centrally active 5-HT receptor agonists and antagonists

D. Middlemiss, M. Tricklebank, 1992, Neuroscience & Biobehavioral Reviews.

NMDA receptors assessed by autoradiography with [3H]L-689,560 are present but not enriched on corticofugal-projecting pyramidal neurones

M. Pangalos, D. Middlemiss, P. Francis, 1992, Brain Research.

Acute and chronic administration of the selective D(3) receptor antagonist SB-277011-A alters activity of midbrain dopamine neurons in rats: an in vivo electrophysiological study.

J. Hagan, D. Middlemiss, Y. Minabe, 2000, The Journal of pharmacology and experimental therapeutics.

Ligands for the investigation of 5-HT autoreceptor function

D. Middlemiss, G. W. Price, C. Roberts, 2001, Brain Research Bulletin.

Pharmacological analysis of the behavioural and thermoregulatory effects of the putative 5-HT1 receptor agonist, RU 24969, in the rat

J. Neill, D. Middlemiss, M. Tricklebank, 1986, Neuropharmacology.

Characterization of MDL 73005EF as a 5‐HT1A selective ligand and its effects in animal models of anxiety: comparison with buspirone, 8‐OH‐DPAT and diazepam

D. Middlemiss, J. Fozard, M. Tricklebank, 1990, British journal of pharmacology.

Subtypes of the 5-HT receptor mediating the behavioural responses to 5-methoxy-N,N-dimethyltryptamine in the rat.

D. Middlemiss, J. Fozard, M. Tricklebank, 1985, European journal of pharmacology.

Effect of chronic antidepressant treatment and subsequent withdrawal on [3H]-5-hydroxytryptamine and [3H]-spiperone binding in rat frontal cortex and serotonin receptor mediated behaviour

D. Middlemiss, C. Marsden, J. Stolz, 2004, Psychopharmacology.

3,4-Dihydro-2H-benzoxazinones are 5-HT(1A) receptor antagonists with potent 5-HT reuptake inhibitory activity.

D. Middlemiss, C. Scott, G. W. Price, 2005, Bioorganic & medicinal chemistry letters.

Enhancement of 5-HT1B and 5-HT1D receptor antagonist effects on extracellular 5-HT levels in the guinea-pig brain following concurrent 5-HT1A or 5-HT re-uptake site blockade

D. Middlemiss, C. Routledge, C. Roberts, 1999, Neuropharmacology.

Differential effects of 5-HT1B/1D receptor antagonists in dorsal and median raphe innervated brain regions.

D. Middlemiss, C. Routledge, A. Belenguer, 1998, European journal of pharmacology.

Further evidence for an interaction of propranolol with the central 5-hydroxytryptamine (5-HT) receptor [proceedings].

D. Middlemiss, M. Stone, D. J. Connell, 1980, British journal of pharmacology.

5-Hydroxytryptamine receptors in GtoPdb v.2023.1

G. Martin, J. Hensler, B. Roth, 2023, IUPHAR/BPS Guide to Pharmacology CITE.

The discovery and development of 5-HT-terminal autoreceptor antagonists.

D. Middlemiss, F. King, P. Wyman, 2003, Progress in medicinal chemistry.

The effect of SB-236057-A, a selective 5-HT1B receptor inverse agonist, on in vivo extracellular 5-HT levels in the freely-moving guinea-pig

J. Hagan, D. Middlemiss, P. Wyman, 2000, Naunyn-Schmiedeberg's Archives of Pharmacology.

A pharmacological analysis of the 5-HT receptor mediating inhibition of 5-HT release in the guinea-pig frontal cortex.

D. Middlemiss, S. Smith, M. Bremer, 1988, European journal of pharmacology.

Supersensitivity of nigral serotonin receptors and rat rotational behaviour.

D. Middlemiss, B. Cox, T. Blackburn, 1981, European journal of pharmacology.

5‐HT2C receptor antagonists: Potential in schizophrenia

Christian A. Heidbreder, D. Middlemiss, M. Wood, 2001 .

GR127935 acts as a partial agonist at recombinant human 5-HT1Dα and 5-HT1Dβ receptors

D. Middlemiss, G. W. Price, J. Watson, 1996 .

8-Hydroxy-2-(di-n-propylamino) tetralin is devoid of activity at the 5-hydroxytryptamine autoreceptor in rat brain. Implications for the proposed link between the autoreceptor and the [3H] 5-HT recognition site

D. Middlemiss, 1984, Naunyn-Schmiedeberg's Archives of Pharmacology.

Stereoselective blockade at the 5-HT autoreceptor and inhibition of radioligand binding to central 5-HT recognition sites by the optical isomers of methiothepin

D. Middlemiss, M. Hibert, 1986, Neuropharmacology.

Importance of h5-HT1B Receptor Selectivity for 5-HT Terminal Autoreceptor Activity: an In Vivo Microdialysis Study in the Freely-moving Guinea-pig

D. Middlemiss, G. W. Price, C. Routledge, 1997, Neuropharmacology.

Serotonin Neurones and Receptors in Alzheimer’s Disease

D. Middlemiss, A. Palmer, D. Bowen, 1986 .

Adenosine receptors in the heart: controversy about signal transmission

D. Middlemiss, M. Spedding, 1985 .

Implantation of a Slow Release Corticosterone Pellet Induces Long‐Term Alterations in Serotonergic Neurochemistry in the Rat Brain

D. Middlemiss, K. Fone, C. Marsden, 2003, Journal of neuroendocrinology.

Binding of the Novel Serotonin Agonist 8‐Hydroxy‐2‐(Di‐n‐Propylamino) Tetralin in Normal and Alzheimer Brain

D. Middlemiss, A. Palmer, D. Bowen, 1986, Journal of neurochemistry.

8-Piperazinyl-2,3-dihydropyrrolo[3,2-g]isoquinolines: potent, selective, orally bioavailable 5-HT1 receptor ligands.

D. Middlemiss, C. Scott, G. W. Price, 2005, Bioorganic & medicinal chemistry letters.

Characterization of [125I]‐SB‐258585 binding to human recombinant and native 5‐HT6 receptors in rat, pig and human brain tissue

D. Middlemiss, G. W. Price, S. Bromidge, 2000 .

Characterization of SB‐271046: A potent, selective and orally active 5‐HT6 receptor antagonist

D. Middlemiss, G. W. Price, S. Bromidge, 2000, British journal of pharmacology.

Pharmacological characterization of extracellular acidification rate responses in human D2(long), D3 and D4.4 receptors expressed in Chinese hamster ovary cells

D. Middlemiss, G. Stemp, I. Boyfield, 1999, British journal of pharmacology.

Relationship between inhibition of cyclic AMP production in Chinese hamster ovary cells expressing the rat D2(444) receptor and antagonist/agonist binding ratios

D. Middlemiss, C. Ragan, E. Harley, 1995, British journal of pharmacology.

Functional characterisation of the human cloned 5‐HT7 receptor (long form); antagonist profile of SB‐258719

J. Hagan, D. Middlemiss, I. Forbes, 1998, British journal of pharmacology.

Design and synthesis of trans-N-[4-[2-(6-cyano-1,2,3, 4-tetrahydroisoquinolin-2-yl)ethyl]cyclohexyl]-4-quinolinecarboxamide (SB-277011): A potent and selective dopamine D(3) receptor antagonist with high oral bioavailability and CNS penetration in the rat.

J. Hagan, D. Middlemiss, K. Thewlis, 2000, Journal of medicinal chemistry.

The endogenous lipid anandamide is an agonist AT rat and human vanilloid (VR1) receptors.

D. Middlemiss, John B Davis, D. Smart, 2000 .

Species differences in 5-HT autoreceptors

D. Middlemiss, G. W. Price, J. Watson, 1995, Behavioural Brain Research.

Stereoselective actions of the isomers of metitepine at 5-HT1D receptors in the guinea pig brain

D. Middlemiss, M. Hibert, L. Wilkinson, 1993, Neuropharmacology.

Functional Correlates of the Subtypes of the 5-ht1 Recognition Site

D. Middlemiss, 1986 .

[3H]L-694,247 labels the 5-HT1Dβ receptor in pig caudate membranes

D. Middlemiss, S. Osborne, M. Beer, 1994 .

GR127935 acts as a partial agonist at recombinant human 5-HT1D alpha and 5-HT1D beta receptors.

D. Middlemiss, G. W. Price, J. Watson, 1996, European journal of pharmacology.

5-HT1A receptor activation increases hippocampal acetylcholine efflux and motor activity in the guinea pig: agonist efficacy influences functional activity in vivo.

D. Middlemiss, P. Hutson, L. Wilkinson, 1994, The Journal of pharmacology and experimental therapeutics.

Stereoselective antagonism of NMDA-stimulated noradrenaline release from rat hippocampal slices by MK-801

D. Middlemiss, R. Ransom, M. Lalies, 1988, Neuroscience Letters.

Stereospecificity of behavioural effects of viloxazine in bulbectomized rats does not correlate with its 5‐HT‐releasing action in vitro

D. Middlemiss, D. Greenwood, J. Kemp, 1982, The Journal of pharmacy and pharmacology.

Effect of haloperidol and (−)-sulpiride on dopamine agonist-induced hypoactivity

D. Middlemiss, C. Reavill, V. Storey, 1995, Neuropharmacology.

Central effects of Ca2+ antagonists

D. Middlemiss, M. Spedding, 1985 .

Receptor Binding Correlates of Functional Terminal 5-HT Autoreceptors

D. Middlemiss, M. Tricklebank, S. Smith, 1990 .

Design and synthesis of 2-naphthoate esters as selective dopamine D4 antagonists.

J. Hagan, D. Middlemiss, G. Riley, 1996, Journal of medicinal chemistry.

5-Hydroxytryptamine1A but not 5-hydroxytryptamine2 receptors are enriched on neocortical pyramidal neurones destroyed by intrastriatal volkensin.

M. Pangalos, D. Middlemiss, P. Francis, 1992, The Journal of pharmacology and experimental therapeutics.

Autoradiographic localization of 5-CT-insensitive 5-HT1-like recognition sites in guinea pig and rat brain

D. Middlemiss, M. Beer, J. Stanton, 1996, Neuropharmacology.

The effect of SB‐269970, a 5‐HT7 receptor antagonist, on 5‐HT release from serotonergic terminals and cell bodies

C. Langmead, J. Hagan, D. Middlemiss, 2001, British journal of pharmacology.

Selective loss of serotonin recognition sites in the parietal cortex in Alzheimer's disease

D. Middlemiss, A. Procter, D. Bowen, 1988 .

5-Carboxamidotryptamine-insensitive 5-HT1-like receptors are concentrated in guinea pig but not rat, claustrum.

D. Middlemiss, M. Beer, J. Stanton, 1993, European journal of pharmacology.

Design and synthesis of trans-3-(2-(4-((3-(3-(5-methyl-1,2,4-oxadiazolyl))- phenyl)carboxamido)cyclohexyl)ethyl)-7-methylsulfonyl-2,3,4,5-tetrahydro-1H-3-benzazepine (SB-414796): a potent and selective dopamine D3 receptor antagonist.

J. Hagan, G. Macdonald, D. Middlemiss, 2003, Journal of medicinal chemistry.

The 5-HT hypothesis of depression revisited.

D. Middlemiss, C. Routledge, 1996, Molecular psychiatry.

Preparation of a stable, highly‐active solubilized adenylate cyclase from rat cerebellum

D. Middlemiss, T. Franklin, 1975, FEBS Letters.

In vivo labelling of the NMDA receptor channel complex by [3H]MK-801.

D. Middlemiss, M. Tricklebank, E H F Wong, 1988, European journal of pharmacology.

Structure and activity of hydrogenated derivatives of (+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine (MK-801).

J. Kemp, D. Middlemiss, T. Lyle, 1990, Journal of medicinal chemistry.